Dr. Camp Awarded $1M for Pancreas Adenocarcinoma Study

Dr. E. Ramsay Camp, professor and chief in the Division of Surgical Oncology, has received $1M in funding plus a supply of pembrolizumab from the Merck Investigator Studies Program. The goal of Dr. Camp’s study, entitled “Phase II Study of  Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas,” is to determine if the chemo-immunotherapy combination will lead to improved clinical response and pathological evidence of enhanced immune cell infiltration into surgically resected tumors. This trial will investigate how pembrolizumab and folfirinox induce changes within the tumor immune microenvironment that can be leveraged in the design of next-generation immunotherapy clinical trials.